Article
Glioblastoma mutations impair ligand discrimination by EGFR
2021-05-04
Abstract excerpt
<h4>SUMMARY</h4> The epidermal growth factor receptor (EGFR) is frequently mutated in human cancer, and is an important therapeutic target. EGFR inhibitors have been successful in lung cancer, where the intracellular tyrosine kinase domain is mutated, but not in glioblastoma multiforme (GBM) – where mutations (or deletions) occur exclusively in the EGFR extracellular region. Wild-type EGFR is known to elicit dist...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ded5ac5d-d959-5670-981d-eac85d89e366
- DOI
- 10.1101/2021.05.04.442654
